As many philosophers have noted, life often travels in cycles. Almost two years and more than 100 episodes ago, on a virtual call far far away, two young oncologists started on a journey to bring the latest oncology evidence to anyone with ears and the will to listen. Now, for episode number 101, Josh and Michael return to where it all started: prostate cancer. Much has changed in the (nearly) two years since that episode, and so in this episode, our hosts provide an update on two more recent updates in the prostate cancer space: Michael discusses TALAPRO-2, the latest in a flurry of studies examining patients with homologous-repair-deficient prostate cancer examining enzalutamide and talazoparib. Josh presents a study close to his heart; ENZA-P is an Australian-led study combining novel anti-androgen agents with the even-more-novel radioactive agent Lutetium-PSMA. Both represent the crest of the new wave of targeted prostate cancer treatment, and there are many tidbits to be gobbled up in this, the start of a new 100 episode cycle for Oncology for the Inquisitive Mind!

Links to articles discussed in this episode (subscription may be required):

TALAPRO-2: https://www.nature.com/articles/s41591-023-02704-x

ENZA-P: https://www.sciencedirect.com/science/article/pii/S1470204524001359?dgcid=coauthor

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.